The University of Texas M.D. Anderson Cancer Center is a freestanding, categorical academic institution established within the University of Texas System by the Texas legislature in Houston in 1941. In 1954, the M.D. Anderson was moved to its current location in the Texas Medical Center in close proximity to other leading biomedical research institutions. The mission of the M.D. Anderson is to eliminate cancer and allied diseases as significant health problems throughout Texas, the nation and the world by developing and maintaining integrated quality programs in patient care, research, education and prevention. M.D. Anderson is dedicated wholly to the study of cancer involving a continuum of research in the basic sciences, clinical investigations and population- based research, with an emphasis on multi-disciplinary translational activities. Faculty investigators are engaged in the transfer of new technology and basic laboratory advances to the clinic, in providing cutting-edge clinical programs including both inpatient and outpatient care, and in community outreach aimed primarily at screening and early detection. The research activities of M.D. Anderson are organized into 28 research programs which include 7 basic science research programs, 18 clinical research programs consisting of 11 disciplinary disease-site programs and 7 thematic programs, and 3 population-based research programs as described in this renewal. The research is supported by the 13 CCSG Core Facilities described in the application for which funding is requested These include 11 currently funded facilities: Automated Cytometry and Cell sorter/Confocal Microscopy and Image Analysis, High Resolution Electron Microscope. Tissue Procurement and Banking, Centralized Histopathology, Research Animal Support, Veterinary Research Support, Cancer Information Systems, Biostatistical Resource Group, Macromolecular Analysis, Synthetic Antigen Laboratory, and Clinical Trials Support, as well as two new facilities, the Pharmacology and Analytical Center and a Central Media Laboratory. Funds are also requested for the Protocol Review and Monitoring System, for Center and a Central Media Laboratory. Funds are also requested for the Protocol Review and Monitoring System, for Development, Planning and Evaluation, and for partial salary support for Senior Leadership and Program Directors.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-26
Application #
6402503
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1978-07-01
Project End
2003-06-30
Budget Start
2001-08-01
Budget End
2002-06-30
Support Year
26
Fiscal Year
2001
Total Cost
$5,343,004
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
001910777
City
Houston
State
TX
Country
United States
Zip Code
77030
Li, Jialu; Fu, Chunxiao; Speed, Terence P et al. (2018) Accurate RNA Sequencing From Formalin-Fixed Cancer Tissue To Represent High-Quality Transcriptome From Frozen Tissue. JCO Precis Oncol 2018:
Fujii, Takeo; Colen, Rivka R; Bilen, Mehmet Asim et al. (2018) Incidence of immune-related adverse events and its association with treatment outcomes: the MD Anderson Cancer Center experience. Invest New Drugs 36:638-646
Hoover, Diana Stewart; Wetter, David W; Vidrine, Damon J et al. (2018) Enhancing Smoking Risk Communications: The Influence of Health Literacy and Message Content. Ann Behav Med 52:204-215
Franco, Hector L; Nagari, Anusha; Malladi, Venkat S et al. (2018) Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res 28:159-170
Altok, Muammer; Achim, Mary F; Matin, Surena F et al. (2018) A decade of robot-assisted radical prostatectomy training: Time-based metrics and qualitative grading for fellows and residents. Urol Oncol 36:13.e19-13.e25
Patel, Sameer H; Kim, Bradford J; Tzeng, Ching-Wei D et al. (2018) Reduction of Cardiopulmonary/Renal Complications with Serum BNP-Guided Volume Status Management in Posthepatectomy Patients. J Gastrointest Surg 22:467-476
Assi, Rita; Kantarjian, Hagop; Ravandi, Farhad et al. (2018) Immune therapies in acute myeloid leukemia: a focus on monoclonal antibodies and immune checkpoint inhibitors. Curr Opin Hematol 25:136-145
Viswanath, Pavitra; Peng, Shaohua; Singh, Ratnakar et al. (2018) A Novel Method for Quantifying Total Thoracic Tumor Burden in Mice. Neoplasia 20:975-984
Ma, Grace X; Lee, Minsun M; Tan, Yin et al. (2018) Efficacy of a community-based participatory and multilevel intervention to enhance hepatitis B virus screening and vaccination in underserved Korean Americans. Cancer 124:973-982
Peng, Guang; Mills, Gordon B (2018) Surviving Ovarian Cancer: An Affair between Defective DNA Repair and RB1. Clin Cancer Res 24:508-510

Showing the most recent 10 out of 12418 publications